Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-v5vhk Total loading time: 0 Render date: 2024-06-21T00:41:35.932Z Has data issue: false hasContentIssue false

1.11 - Electroconvulsive Therapy and Other Non-Pharmacological Treatments

from Part I - Treatment Strategies

Published online by Cambridge University Press:  19 October 2021

Edited by
Michael Cummings  and
Stephen Stahl
Michael Cummings
Affiliation:
University of California, Los Angeles
Stephen Stahl
Affiliation:
University of California, San Diego
Get access

Summary

Electroconvulsive therapy (ECT) was initially utilized in the treatment of schizophrenia in the 1930s. ECT involves applying an electrical current to the brain to induce a therapeutic seizure [1]. Muscle relaxants were not available early on so adverse effects of ECT included fractures due to vigorous muscle contractions during the seizure. These undesirable effects, stigma, and the availability of alternative antipsychotic medications led to ECT falling out of favor [2].

Type
Chapter
Information
Management of Complex Treatment-resistant Psychotic Disorders , pp. 80 - 85
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Kennedy, S. H., Milev, R., Giacobbe, P., et al. (2009). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies. J Affect Disord, 117 Suppl. 1, S44–53.CrossRefGoogle Scholar
Poublon, N. A., Haagh, M., et al. (2011). The efficacy of ECT in the treatment of schizophrenia. A systematic review. Erasmus J Med, 2(1), 48.Google Scholar
Brenner, H. D., Dencker, S. J., Goldstein, M. J., et al. (1990). Defining treatment refractoriness in schizophrenia. Schizophr Bull, 16, 551–561.CrossRefGoogle ScholarPubMed
Conley, R. R., Buchanan, R. W. (1997). Evaluation of treatment-resistant schizophrenia. Schizophr Bull, 23, 663–674.CrossRefGoogle ScholarPubMed
Meltzer, H. Y. (1997). Treatment-resistant schizophrenia – the role of clozapine. Curr Med Res Opin, 14, 1–20.CrossRefGoogle ScholarPubMed
Meltzer, H. Y. (1992). Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull, 18, 515–542.CrossRefGoogle ScholarPubMed
Remington, G., Saha, A., Chong, S. A., et al. (2005). Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs, 19, 843–872.CrossRefGoogle ScholarPubMed
Tranulis, C., Mouaffak, F., Chouchana, L., et al. (2006). Somatic augmentation strategies in clozapine resistance – what facts? Clin Neuropharmacol, 29, 34–44.Google Scholar
Cipriani, A., Boso, M., Barbui, C. (2009). Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev, 8(3), CD006324.Google Scholar
Porcelli, S., Balzarro, B., Serretti, A. (2012). Clozapine resistance: augmentation strategies. Eur Neuropsychopharmacol, 22, 165–182.CrossRefGoogle ScholarPubMed
Taylor, D. M., Smith, L., Gee, S. H., et al. (2012). Augmentation of clozapine with a second antipsychotic – a meta-analysis. Acta Psychiatr Scand, 125, 15–24.CrossRefGoogle ScholarPubMed
American Psychiatric Association. (2001). The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging: A Task Force Report of the American Psychiatric Association. Washington, D.C.Google Scholar
Tharyan, P., Adams, C. E. (2005). Electroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev, 18(2), CD000076.Google Scholar
Pompili, M., Lester, D., Dominici, G., et al. (2013). Indications for electroconvulsive treatment in schizophrenia: a systematic review. Schizophr Res, 146, 1–9.CrossRefGoogle ScholarPubMed
Gazdag, G., Kocsis-Ficzere, N., Tolna, J. (2006). The augmentation of clozapine treatment with electroconvulsive therapy. Ideggyogy Sz, 59, 261–267.Google ScholarPubMed
Small, J. G., Milstein, V., Klapper, M., Kellams, J.J., Small, I.F. (1982). ECT combined with neuroleptics in the treatment of schizophrenia. Psychopharmacol Bull, 18(2), 34–35.Google Scholar
Abraham, K. R., Kulhara, P. (1987). The efficacy of electroconvulsive therapy in the treatment of schizophrenia. A comparative study. Br J Psychiatry, 151, 152–155.CrossRefGoogle ScholarPubMed
Petrides, G., Malur, C., Braga, R. J., et al. (2015). Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry, 172, 52–58.CrossRefGoogle ScholarPubMed
Grover, S., Hazari, N., Kate, N. (2015). Combined use of clozapine and ECT: a review. Acta Neuropsychiatr, 27, 131–142.CrossRefGoogle ScholarPubMed
Leucht, S., Tardy, M., Komossa, K., et al. (2012). Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev, 2012, CD008016.Google Scholar
Zipursky, R. B., Menezes, N. M., Streiner, D. L. (2014). Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res, 152, 408–414.CrossRefGoogle ScholarPubMed
Sackeim, H. A., Haskett, R. F., Mulsant, B. H., et al. (2001). Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA, 285, 1299–1307.CrossRefGoogle ScholarPubMed
Ward, H. B., Szabo, S. T., Rakesh, G. (2018). Maintenance ECT in schizophrenia: a systematic review. Psychiatry Res, 264, 131–142.CrossRefGoogle ScholarPubMed
Chanpattana, W., Chakrabhand, M. L., Sackeim, H. A., et al. (1999). ECT in treatment-resistant schizophrenia: a controlled study. Journal of ECT, 15(3), 178–192.Google Scholar
Yang, Y., Cheng, X., Xu, Q., et al. (2016). The maintenance of modified electroconvulsive therapy combined with risperidone is better than risperidone alone in preventing relapse of schizophrenia and improving cognitive function. Arq Neuropsiquiatr, 10, 823–828.CrossRefGoogle Scholar
Maley, C. T., Becker, J. E., Shultz, E. K. B. (2019). Electroconvulsive therapy and other neuromodulation techniques for the treatment of psychosis. Child Adolesc Psychiatr Clin N Am, 28, 91–100.CrossRefGoogle ScholarPubMed
Freitas, C., Fregni, F., Pascual-Leone, A. (2009). Meta-analysis of the effects of repetitive transcranial magnetic stimulation (rTMS) on negative and positive symptoms in schizophrenia. Schizophr Res, 108(1–3), 11–24.CrossRefGoogle ScholarPubMed
Slotema, C. W., Blom, J. D., van Lutterveld, R., et al. (2014). Review of the efficacy of transcranial magnetic stimulation for auditory verbal hallucinations. Biol Psychiatry, 76, 101–110.CrossRefGoogle ScholarPubMed
Nieuwdorp, W., Koops, S., Somers, M., et al. (2015). Transcranial magnetic stimulation, transcranial direct current stimulation and electroconvulsive therapy for medication-resistant psychosis of schizophrenia. Curr Opin Psychiatry, 28, 222–228.CrossRefGoogle ScholarPubMed
Dlabac-de Lange, J. J., Knegtering, R., Aleman, A. (2010). Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: review and meta-analysis. J Clin Psychiatry, 71, 411–418.CrossRefGoogle ScholarPubMed
Prikryl, R., Kucerova, H. (2013). Can repetitive transcranial magnetic stimulation be considered an effective treatment option for negative symptoms of schizophrenia? Journal of ECT, 29(1), 67–74.CrossRefGoogle ScholarPubMed
Shi, C., Yu, X., Cheung, E., et al. (2014). Revisiting the therapeutic effect of rTMS on negative symptoms in schizophrenia: a meta-analysis. Psychiatry Res, 215(3), 505–513.CrossRefGoogle ScholarPubMed
Zhou, K., Tang, Y., Song, Z., et al. (2019). Repetitive transcranial magnetic stimulation as an adjunctive treatment for negative symptoms and cognitive impairment in patients with schizophrenia: a randomized, double-blind, sham-controlled trial. Neuropsychiatr Dis Treat, 15, 1141–1150.CrossRefGoogle Scholar
Marzouk, T., Winkelbeiner, S., Azizi, H., et al. (2019). Transcranial magnetic stimulation for positive symptoms in schizophrenia: a systematic review. Neuropsychobiology, 10, 1–13.Google Scholar
Arumugham, S. S., Thirthalli, J., Andrade, C. (2016). Efficacy and safety of combining clozapine with electrical or magnetic brain stimulation in treatment-refractory schizophrenia. Expert Rev Clin Pharmacol, 9, 1245–1252.CrossRefGoogle ScholarPubMed
Narayana, S., Papanicolaou, A. C., McGregor, A., et al. (2015). Clinical applications of transcranial magnetic stimulation in pediatric neurology. J Child Neurol, 30, 1111–1124.CrossRefGoogle ScholarPubMed
Brunelin, J., Mondino, M., Gassab, L., et al. (2012). Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia. Am J Psychiatry, 169, 719–724.CrossRefGoogle ScholarPubMed
Mervis, J. E., Capizzi, R. J., Boroda, E., et al. (2017). Transcranial direct current stimulation over the dorsolateral prefrontal cortex in schizophrenia: a quantitative review of cognitive outcomes. Front Hum Neurosci, 11, 44.CrossRefGoogle ScholarPubMed
Fitzgerald, P. B., McQueen, S., Daskalakis, Z. J., et al. (2014). A negative pilot study of daily bimodal transcranial direct current stimulation in schizophrenia. Brain Stimul, 7, 813–816.CrossRefGoogle ScholarPubMed
Frohlich, F., Burrello, T. N., Mellin, J. M., et al. (2016). Exploratory study of once-daily transcranial direct current stimulation (tDCS) as a treatment for auditory hallucinations in schizophrenia. Eur Psychiatry, 33, 54–60.CrossRefGoogle ScholarPubMed
Narita, Z., Stickley, A., DeVylder, J., et al. (2019). Effect of multi-session prefrontal transcranial direct current stimulation on cognition in schizophrenia: a systematic review and meta-analysis. Schizophr Res, 216, 367–373.Google Scholar
Hasan, A., Wolff-Menzler, C., Pfeiffer, S., et al. (2015). Transcutaneous noninvasive vagus nerve stimulation (tVNS) in the treatment of schizophrenia: a bicentric randomized controlled pilot study. Eur Arch Psychiatry Clin Neurosci, 265, 589–600.CrossRefGoogle ScholarPubMed
Perez, S. M., Carreno, F. R., Frazer, A., et al. (2014). Vagal nerve stimulation reverses aberrant dopamine system function in the methylazoxymethanol acetate rodent model of schizophrenia. J Neurosci, 34, 9261–9267.Google Scholar
Smucny, J., Visani, A., Tregellas, J. R. (2015). Could vagus nerve stimulation target hippocampal hyperactivity to improve cognition in schizophrenia? Front Psychiatry, 6, 43.CrossRefGoogle ScholarPubMed
Blumer, D., Davies, K., Alexander, A., et al. (2001). Major psychiatric disorders subsequent to treating epilepsy by vagus nerve stimulation. Epilepsy Behav, 2, 466–472.CrossRefGoogle ScholarPubMed
Keller, S., Lichtenberg, P. (2008). Psychotic exacerbation in a patient with seizure disorder treated with vagus nerve stimulation. Isr Med Assoc J, 10, 550–551.Google Scholar
Mikell, C. B., McKhann, G. M., Segal, S., et al. (2009). The hippocampus and nucleus accumbens as potential therapeutic targets for neurosurgical intervention in schizophrenia. Stereotact Funct Neurosurg, 87, 256–265.CrossRefGoogle ScholarPubMed
Kuhn, J., Bodatsch, M., Sturm, V., et al. (2014). Deep brain stimulation in schizophrenia. Act Nerv Super, 3, 69–78.CrossRefGoogle Scholar
Gault, J. M., Davis, R., Cascella, N. G., et al. (2018). Approaches to neuromodulation for schizophrenia. J Neurol Neurosurg Psychiatry, 89, 777–787.CrossRefGoogle ScholarPubMed
Schermer, M. (2011). Ethical issues in deep brain stimulation. Front Integr Neurosci, 5, 17.CrossRefGoogle ScholarPubMed
Benazzi, F. (2006). Various forms of depression. Dialogues Clin Neurosci, 8, 151–161.CrossRefGoogle ScholarPubMed
Aichhorn, W., Stelzig-Schoeler, R., Geretsegger, C., et al. (2007). Bright light therapy for negative symptoms in schizophrenia: a pilot study. J Clin Psychiatry, 68, 1146.CrossRefGoogle ScholarPubMed
Roopram, S. M., Burger, A. M., van Dijk, D. A., et al. (2016). A pilot study of bright light therapy in schizophrenia. Psychiatry Res, 245, 317–320.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×